Translational Development Acquisition (TDACW) Cash & Equivalents (2023 - 2026)

Translational Development Acquisition (TDACW) has reported Cash & Equivalents for 4 consecutive years, with $85877.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents rose 143.59% year-over-year to $85877.0; the trailing twelve-month figure through Jun 2026 stood at $85877.0 (up 143.59% YoY), and the FY2025 full-year result was $29787.0, down 93.2% from the prior year.
• Cash & Equivalents rose to $85877.0 in Q2 2026 per TDACW's latest filing, from $24630.0 in the prior quarter.
• Across five years, Cash & Equivalents topped out at $438174.0 in Q4 2024 and bottomed at $2021.0 in Q4 2023.
• Historically, Cash & Equivalents has averaged $108686.8 across 4 years, with a median of $41202.5 in 2025.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents soared 21581.05% in 2024, then slumped 93.2% in 2025.
• Over 4 years, Cash & Equivalents stood at $2021.0 in 2023, then jumped by 21581.05% to $438174.0 in 2024, then plunged by 93.2% to $29787.0 in 2025, then surged by 188.3% to $85877.0 in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $85877.0, $24630.0, and $29787.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.